JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-F) Long-Term Capital Lease Obligation : ฿130.76 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is JSP Pharmaceutical Manufacturing (Thailand) PCL Long-Term Capital Lease Obligation?

JSP Pharmaceutical Manufacturing (Thailand) PCL's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was ฿130.76 Mil.

JSP Pharmaceutical Manufacturing (Thailand) PCL's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (฿128.27 Mil) to Dec. 2023 (฿125.67 Mil) but then increased from Dec. 2023 (฿125.67 Mil) to Mar. 2024 (฿130.76 Mil).

JSP Pharmaceutical Manufacturing (Thailand) PCL's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (฿98.09 Mil) to Dec. 2022 (฿113.99 Mil) and increased from Dec. 2022 (฿113.99 Mil) to Dec. 2023 (฿125.67 Mil).

JSP Pharmaceutical Manufacturing (Thailand) PCL Long-Term Capital Lease Obligation Historical Data

The historical data trend for JSP Pharmaceutical Manufacturing (Thailand) PCL's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JSP Pharmaceutical Manufacturing (Thailand) PCL Long-Term Capital Lease Obligation Chart

JSP Pharmaceutical Manufacturing (Thailand) PCL Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

3.10

35.81

98.09

113.99

125.67

JSP Pharmaceutical Manufacturing (Thailand) PCL Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial										107.53	125.58	128.27	125.67	130.76

JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-F) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

JSP Pharmaceutical Manufacturing (Thailand) PCL Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of JSP Pharmaceutical Manufacturing (Thailand) PCL's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-F) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-F) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 255 and 257, Soi Sathupradit, 58, Bang Pongphang, Yannawa, Bangkok, THA, 10120

Website

https://www.jsppharma.com

JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing drugs, dietary supplements, cosmetics, herbs, and dietary supplements in the form of vitamins including healthy coffee Ready. Its segments include Manufacturing and distribution of products under the customer's Brand name and Own Brand name. The majority of the revenue comes from the manufacturing and distribution of products under the customer's brand name. The Group is managed and operates principally in Thailand.

JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-F) Headlines

No Headlines